CNST News and Press, Constellation Pharmaceuticals Inc. From 06/21/21

NEW YORK, NY / ACCESSWIRE / June 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) concerning potential violations of the federal securities laws and/or breaches of fid...

Christian Kaspar-Bartke/Getty Images News BofA downgrades CureVac following disappointing COVID vaccine data Following the release yesterday of disappointing data in a phase 2b/3 trial of its COVID-19 vaccine, BofA Securities has downgraded shares of CureVac (CVAC) from buy to neutral and cut...

Constellation Pharmaceuticals ([[CNST]] -0.1%) announced that the data from MANIFEST Phase 2 clinical trial for pelabresib (CPI-0610) in myelofibrosis ((MF)) were published online in association with the European Hematology Association ((EHA)) annual meeting. “We are particularly ...

Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...

NEW YORK, NY / ACCESSWIRE / June 10, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Diamond S Shipping Inc. (NYSE:DSSI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties ...

Regional bank consolidation continues with three new bank deals announced last week. Extended Stay America catches a higher bid. Chamath Palihapitiya files for four new biotech-focused SPACs. For further details see: Merger Arbitrage Mondays: Extended Stay America Receiv...

Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapy Oral, once-daily 350mg dose selected for Phase 2 Enrollment of tumor-specific expansion cohorts is ongoing CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) ...

Shares of MorphoSys (NASDAQ: MOR) sank 11.5% this week as of the market close on Thursday. The decline stemmed from the German drugmaker's announcement on Wednesday that it plans to acquire Constellation Pharmaceuticals (NASDAQ: CNST) for $1.7 billion. MorphoSys also said th...

The stock of Constellation Pharmaceuticals (NASDAQ: CNST) was absolutely crushing it this week, up 70.6% as of the market close on Thursday. The catalyst behind this impressive performance was the announcement on Wednesday that German drugmaker MorphoSys (NASDAQ: MOR) plans ...

Constellation Pharmaceuticals ([[CNST]] +67.2%) has risen more than two-thirds in value after agreeing to be acquired by German biotech MorphoSys AG (MOR) in a deal valued at $1.7B.The offer price of $34.00 per share in cash for Constellation’s common stock indicates a premium of ...